Phenotypic Drug Discovery

Phenotypic Drug Discovery: History, Evolution, Future; Development and Validation of Disease Assays for Phenotypic Screening; The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screening; CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screening; Contemporary Techniques for Target Deconvolution and Mode of Action Elucidation; Artificial Intelligence as an Enabler for Phenotypic Drug Discovery; Public–Private Partnerships to Advance Phenotypic Drug Discovery; Identification of a Novel Class
of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening; Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447); Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia; Phenotypic Screening for Drug Discovery in Tuberculosis; Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers; Phenotypic Screen Leads to Identification of Novel Posttranscriptional Regulation Machinery for HBV